<DOC>
	<DOCNO>NCT00410696</DOCNO>
	<brief_summary>The primary objective study evaluate efficacy safety pegfilgrastim versus filgrastim , administer high-dose chemotherapy peripheral stem cell reinfusion .</brief_summary>
	<brief_title>Pegfilgrastim Versus Filgrastim After High-dose Chemotherapy</brief_title>
	<detailed_description>Secondary objective evaluate immunological reconstitution pegfilgrastim filgrastim .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Patients hematological neoplasm solid tumor candidable highdose chemotherapy autologous peripheral stem cell reinfusion Adequate organ function Written inform consent . Use experimental drug Active infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>High-dose chemotherapy</keyword>
	<keyword>Growth factor</keyword>
	<keyword>Pegfilgrastim</keyword>
</DOC>